Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up

Basit Öğe Kaydı
dc.authorid0000-0001-5673-8408en_US
dc.contributor.authorSaydam, Güray
dc.contributor.authorHaznedaroğlu, İbrahim Celalettin
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorYavuz, Akif S.
dc.contributor.authorAli, Rıdvan
dc.contributor.authorGüvenç, Birol
dc.contributor.authorAkay, Olga M.
dc.contributor.authorBaşlar, Zafer
dc.contributor.authorÖzbek, Uğur
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorAydın, Demet
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorÜndar, Bulent
dc.contributor.authorDağdaş, Simten
dc.contributor.authorAyyıldız, Mehmet Orhan
dc.contributor.authorAkın, Gülnur
dc.contributor.authorDağ, İlkiz M.
dc.contributor.authorİlhan, Osman
dc.date.accessioned2022-08-08T11:56:14Z
dc.date.available2022-08-08T11:56:14Z
dc.date.issued2018en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.descriptionPMID: 29996726
dc.description.abstractbjectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods: Patients with newly diagnosed Philadelphia chromosome–positive CML in chronic phase (CML-CP; N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) by 12 months, was previously reported (66.1% [80% CI, 59.7%–72.0%]). ClinicalTrials.gov identifier NCT01274351 Results: By 24 months, 83.0% of patients achieved MMR, and 50.9% achieved MR4.5 (BCR-ABL1IS ≤0.0032%). Safety results at 24 months were consistent with those at 12 months. No additional deaths or disease progressions to accelerated phase/blast crisis were observed between 12 and 24 months. Discussion: Treatment with nilotinib 300 mg twice daily for 2 years provided high MMR with a good safety/tolerability profile in newly diagnosed CML-CP patients in Turkey. Assessment of MMR across time points showed increasing rates through 18 months, after which as lower rate of increase was observed. The safety profile of nilotinib 300 mg twice daily with 24 months of follow-up was similar to that observed at 12 months, and no new safety concerns were identified. These efficacy and safety findings are consistent with the results from the 12-month analysis of this study and from previous nilotinib studies. These findings support nilotinib as an option for frontline treatment of CML-CP. Conclusion: Frontline nilotinib treatment provided sustained efficacy, with good tolerability, over 24 months in newly diagnosed CML-CP patients.en_US
dc.identifier.citationSaydam, G., Haznedaroğlu, İ. C., Kaynar, L., Yavuz, A. S., Ali, R., Güvenç, B. ve diğerleri. (2018). Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. Hematology, 23(10), 771-777.en_US
dc.identifier.doi10.1080/10245332.2018.1498167
dc.identifier.endpage777en_US
dc.identifier.issn1024-5332
dc.identifier.issue10en_US
dc.identifier.pmid29996726
dc.identifier.scopus2-s2.0-85049789573
dc.identifier.scopusqualityQ3
dc.identifier.startpage771en_US
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/10245332.2018.1498167
dc.identifier.urihttps://hdl.handle.net/11468/10153
dc.identifier.volume23en_US
dc.identifier.wosWOS:000448137100007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAyyıldız, Mehmet Orhan
dc.language.isoenen_US
dc.publisherTaylor and Francis Ltd.en_US
dc.relation.ispartofHematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBCR-ABL1en_US
dc.subjectChronic myeloid leukemiaen_US
dc.subjectMolecular responseen_US
dc.subjectNilotiniben_US
dc.subjectTyrosine kinase inhibitoren_US
dc.titleFrontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-upen_US
dc.titleFrontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myel _ Enhanced Reader.pdf
Boyut:
8.05 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu